Systematic computational analysis of structure-activity relationships: Concepts, challenges and recent advances

Future Medicinal Chemistry

Volumn 1, Issue 3, 2009, Pages 451-466

  Peltason, Lisa ^a   Bajorath, Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; CATHEPSIN S INHIBITOR; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ELASTASE INHIBITOR; LIPOXYGENASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SQUALENE SYNTHASE INHIBITOR; THROMBIN INHIBITOR;

BINDING SITE; DRUG ACTIVITY; DRUG STRUCTURE; PRIORITY JOURNAL; PROTEINASE INHIBITION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION;

BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTER SIMULATION; ENZYME INHIBITORS; ENZYMES; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350457007     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.41     Document Type: Review

References (35)

1. Eckert H, Bajorath J. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug Discov. Today. 12(5-6), 225-233 (2007).
2. Peltason L, Bajorath J. Molecular similarity analysis uncovers heterogeneous structure-activity relationships and variable activity landscapes. Chem. Biol. 14(5), 489-497 (2007).
3. Maggiora GM. On outliers and activity cliffs-why QSAR often disappoints. J. Chem. Inf. Model. 46(4), 1535 (2006).
4. Todeschini R, Consonni V. Handbook of Molecular Descriptors. Mannhold R, Kubinyi H, Timmerman H (Eds). Wiley-VCH, Weinheim, Germany (2000).
5. Willett P, Barnard JM, Downs GM. Chemical similarity searching. J. Chem. Inf. Comput. Sci. 38(6), 983-996 (1998).
6. Willett P. Similarity-based virtual screening using 2D fingerprints. Drug Discov. Today. 11(23-24), 1046-1053 (2006).
7. MACCS Structural Keys. Symyx Software. CA, USA.
8. Kubinyi H. QSAR in drug design. In: Handbook of Chemoinformatics (Volume 4). Gasteiger J (Ed.). Wiley-VCH, Weinheim, Germany 1532-1554 (2003).
9. Esposito EX, Hopfinger AJ, Madura JD. Methods for applying the quantitative structure-activity relationship paradigm. Methods Mol. Biol. 275, 131-214 (2004).
10. Kubinyi H. QSAR and 3D QSAR in drug design. Part 1: methodology. Drug Discov. Today. 2(11), 457-467 (1997).
11. Benigni R, Bossa C. Predictivity of QSAR. J. Chem. Inf. Model. 48(5), 971-980 (2008).
12. Tetko IV, Sushko I, Pandey AK et al. Critical assessment of QSAR models of environmental toxicity against tetrahymena pyriformis: focusing on applicability domain and overfitting by variable selection. J. Chem. Inf. Model. 48(9), 1733-1746 (2008).
13. Patel Y, Gillet VJ, Howe T et al. Assessment of additive/non-additive effects in structure-activity relationships: implications for iterative drug design. J. Med. Chem. 51(23), 7552-7562 (2008).
14. Kubinyi H. Quantitative structure-activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character. J. Med. Chem. 20(5), 625-629 (1977).
15. Manallack DT, Ellis DD, Livingstone DJ. Analysis of linear and nonlinear QSAR data using neural networks. J. Med. Chem. 37(22), 3758-3767 (1994).
16. Johnson SR. The trouble with QSAR (or how I learned to stop worrying and embrace fallacy). J. Chem. Inf. Model. 48(1), 25-26 (2008).
17. Sheridan RP, Kearsley SK. Why do we need so many chemical similarity search methods? Drug Discov. Today. 7(17), 903-911 (2002).
18. Johnson MA, Maggiora GM (Eds). Concepts and Applications of Molecular Similarity. John Wiley & Sons, NY, USA (1990).
19. Bajorath J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov. 1(11), 882-894 (2002).
20. Sheridan RP, Rusinko A III, Ramaswamy N, Venkataraghavan R. Searching for pharmacophores in large coordinate data bases and its use in drug design. Proc. Natl. Acad. Sci. USA 86(20), 8165-8169 (1989).
21. Renner S, Schneider G. Fuzzy pharmacophore models from molecular alignments for correlation-vector-based virtural screening. J. Med. Chem. 47(19), 4653-4664 (2004).
22. Peltason L, Bajorath J. SAR Index: quantifying the nature of structure-activity relationships. J. Med. Chem. 50(23), 5571-5578 (2007).
23. Patterson DE, Cramer RD, Ferguson AM et al. Neighborhood behavior: a useful concept for validation of 'molecular diversity' descriptors. J. Med. Chem. 39(16), 3049-3059 (1996).
24. Papadatos G, Cooper AWJ, Kadirkamanathan V et al. Analysis of neighborhood behavior in lead optimization and array design. J. Chem. Inf. Model. 49(2), 195-208 (2009).
25. Wawer M, Peltason L, Weskamp N, Teckentrup A, Bajorath J. Structure-activity relationship anatomy by network-like similarity graphs and local structure-activity relationship indices. J. Med. Chem. 51(19), 6075-6084 (2008).
26. Guha R, Van Drie JH. Structure-activity landscape index: identifying and quantifying activity cliffs. J. Chem. Inf. Model. 48(3), 646-658 (2008).
27. Guha R, Van Drie JH. Assessing how well a modeling protocol captures a structure-activity landscape. J. Chem. Inf. Model. 48(8), 1716-1728 (2008).
28. Medina-Franco JL, Martinez-Mayorga K, Bender A et al. Characterization of activity landscapes using 2D and 3D similarity methods: consensus activity cliffs. J. Chem. Inf. Model. 49(2), 477-491 (2009).
29. Gribbon P, Lyons R, Laflin P et al. Evaluating real-life high-throughput screening data. J. Biomol. Screen. 10(2), 99-107 (2005).
30. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in highthroughput screening data analysis. Nat. Biotechnol. 24(2), 167-175 (2006).
31. Wawer M, Peltason L, Bajorath J. Elucidation of structure-activity relationship pathways in biological screening data. J. Med. Chem. 52(4), 1075-1080 (2009).
32. Peltason L, Weskamp N, Teckentrup A, Bajorath J. Exploration of structure-activity relationship determinants in analogue series. J. Med. Chem. 52(10), 3212-3224 (2009).
33. Clark T. QSAR and QSPR based solely on surface properties? J. Mol. Graph. Model. 22(6), 519-525 (2004).
34. Peters MB, Raha K, Merz KM Jr. Quantum mechanics in structure-based design. Curr. Opin. Drug Discov. Develop. 9(3), 370-379 (2006).
35. Molecular Drug Data Report (MDDR), Version 2005.2. Symyx Software, CA, 2005